Picture Berlin Partner Top News Formo Raises $61m for Bio Cheese 650x100px

Document › Details

Uniqure N.V.. (3/1/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences". Lexington, MA & Amsterdam.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Organisation 2	SVB Leerink LLC
	Today	Leerink Partners (Group)
	Group	Leerink Partners (Group)
	Product	SVB Leerink Annual Global Healthcare Conference 2019 New York
	Product 2	BioCapital Europe 2019 Amsterdam
	Index term	Uniqure–Cowen: investor conference, 201903 supply service Uniqure presents at Cowen & Co Annual Health Care Conference 2019
	Index term 2	Uniqure–Barclays: investor conference, 201903 supply service Uniqure presents at Barclays Global Healthcare Conference in Miami
	Person	Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)
	Person 2	van Deventer, Sander (VectorY 202211– CEO + Co-Founder before CTO also Co-Founder of Forbion)

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in March:

Leerink Global Health Care Conference in New York City

> Matt Kapusta, chief executive officer at uniQure, will participate in a fireside chat on Friday, March 1 at 9:30 a.m. ET. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.

Cowen & Co. Healthcare Conference in Boston, Mass.

> Matt Kapusta will present a corporate update on Tuesday, March 12 at 10:40 a.m. ET. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.

Barclays Healthcare Conference in Miami, Florida

> Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure, will present a corporate update and participate in a fireside chat on Wednesday, March 13 at 1:35 p.m. ET. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.

BioCapital Europe by LSP in Amsterdam, the Netherlands

> Christian Klemt, chief accounting officer at uniQure, will present a corporate update on Thursday, March 14 at 2:30 p.m. CET.

Gene Therapy for Rare Disorders Conference in Boston, Mass.

> Daniel Leonard, senior director of global patient advocacy at uniQure, will participate in the panel discussion “Patient Advocacy in the Gene Therapy Space: A Case Study in Hemophilia” on Wednesday, March 27 at 5:30 p.m. ET.

> Jonathan Garen, chief business officer at uniQure, will present “The Emerging Business Models for Commercializing Gene Therapy Treatment for Hemophilia” on Thursday, March 28 at 11 a.m. ET.

Cold Spring Harbor Conference on RNA and Oligonucleotide Therapeutics in Cold Spring Harbor, NY

> Melvin Evers, Ph.D., associate director of emerging technologies at uniQure, will present “Development of microRNA-based gene therapy for Huntington’s disease” at the conference on Thursday, March 28.

> Marina Sogorb-Gonzalez, Ph.D. student at uniQure, will also present “Transfer of therapeutic miRNAs within extracellular vesicles secreted from Huntington’s disease iPSC-derived neurons” at the conference, which takes place March 27-30.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. www.uniQure.com
uniQure Contacts

For Investors: For Media:

Maria E. Cantor Eva M. Mulder Tom Malone
Direct: 339-970-7536 Direct: +31 20 240 6103 Direct: 339-970-7558

Record changed: 2023-06-05